Document Detail


Serum S100beta: a noninvasive marker of blood-brain barrier function and brain lesions.
MedLine Citation:
PMID:  12767094     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: S100beta protein is expressed constitutively by brain astrocytes. Elevated S100beta levels in cerebrospinal fluid and serum reported after head trauma, subarachnoid hemorrhage, and stroke were correlated with the extent of brain damage. Because elevated serum S100beta also was shown to indicate blood-brain barrier (BBB) dysfunction in the absence of apparent brain injury, it remains unclear whether elevation of serum levels of S100beta reflect BBB dysfunction, parenchymal damage, or both.
METHODS: The authors conducted a prospective study of serum S100beta levels in six patients who underwent hyperosmotic BBB disruption (BBBD) with intraarterial chemotherapy for primary central nervous system lymphoma. In addition, 53 serum S100beta samples were measured in 51 patients who had a variety of primary or metastatic brain lesions at the time of neuroimaging.
RESULTS: S100beta was correlated directly with the degree of clinical and radiologic signs of BBBD in patients who were enrolled in the hyperosmotic study. In patients with neoplastic brain lesions, gadolinium enhancement on a magnetic resonance image was correlated with elevated S100beta levels (n = 45 patients; 0.16 +/- 0.1 microg/L; mean +/- standard error of the mean) versus nonenhancing scans (n = 8 patients; 0.069 +/- 0.04 microg/L). Primary brain tumors (n = 8 patients; 0.12 +/- 0.08) or central nervous system metastases also presented with elevated serum S100beta levels (n = 27 patients; 0.14 +/- 0.34). Tumor volume was correlated with serum S100beta levels only in patients with vestibular schwannoma (n = 6 patients; 0.13 +/- 0.10 microg/L) but not in patients with other brain lesions.
CONCLUSIONS: S100beta was correlated directly with the extent and temporal sequence of hyperosmotic BBBD, further suggesting that S100beta is a marker of BBB function. Elevated S100beta levels may indicate the presence of radiologically detectable BBB leakage. Larger prospective studies may better determine the true specificity of S100beta as a marker for BBB function and as an early detection or follow-up marker of brain tumors.
Authors:
Andrew A Kanner; Nicola Marchi; Vincent Fazio; Marc R Mayberg; Michael T Koltz; Vitaly Siomin; Glen H J Stevens; Thomas Masaryk; Barbara Aumayr; Barbara Ayumar; Michael A Vogelbaum; Gene H Barnett; Damir Janigro
Related Documents :
6603834 - Evaluation of the brain-stem function by the auditory brain-stem response and the calor...
11959364 - Functional brain asymmetry and attentional modulation in young and stabilised schizophr...
15596774 - Suicide after successful deep brain stimulation for movement disorders.
2411514 - Is the auditory brain-stem response (abr) effective in the assessment of post-traumatic...
24238574 - The prognostic value of adamts13 (a disintegrin and metalloprotease with thrombospondin...
7579024 - Vitamin b12 deficiency and dementia.
Publication Detail:
Type:  Journal Article; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Cancer     Volume:  97     ISSN:  0008-543X     ISO Abbreviation:  Cancer     Publication Date:  2003 Jun 
Date Detail:
Created Date:  2003-05-26     Completed Date:  2003-06-20     Revised Date:  2014-08-19    
Medline Journal Info:
Nlm Unique ID:  0374236     Medline TA:  Cancer     Country:  United States    
Other Details:
Languages:  eng     Pagination:  2806-13     Citation Subset:  AIM; IM    
Copyright Information:
Copyright 2003 American Cancer Society.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Aged, 80 and over
Biological Markers / blood*
Blood-Brain Barrier / physiology*
Brain Neoplasms / blood,  diagnosis*
Female
Humans
Magnetic Resonance Imaging
Male
Middle Aged
Nerve Growth Factors / blood*
Prospective Studies
S100 Calcium Binding Protein beta Subunit
S100 Proteins / blood*
Grant Support
ID/Acronym/Agency:
HL51614/HL/NHLBI NIH HHS; NS38195/NS/NINDS NIH HHS; NS43284/NS/NINDS NIH HHS; R01 NS049514/NS/NINDS NIH HHS
Chemical
Reg. No./Substance:
0/Biological Markers; 0/Nerve Growth Factors; 0/S100 Calcium Binding Protein beta Subunit; 0/S100 Proteins
Comments/Corrections
Erratum In:
Cancer. 2006;107(9 No 1):2314
Note: Ayumar, Barbara [corrected to Aumayr, Barbara]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  cDNA microarray analysis of gene expression in pathologic Stage IA nonsmall cell lung carcinomas.
Next Document:  Cyclooxygenase-2 expression in human pituitary tumors.